{"id":"o6-benzylguanine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"O6-benzylguanine acts as a suicide substrate for AGT, a DNA repair enzyme that normally protects cells from the cytotoxic effects of alkylating agents like temozolomide and carmustine. By depleting AGT levels, the drug prevents cancer cells from repairing alkylation-induced DNA damage, thereby enhancing the efficacy of concurrent chemotherapy. This mechanism is particularly relevant in tumors with high AGT expression.","oneSentence":"O6-benzylguanine is an alkyltransferase inhibitor that depletes the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), sensitizing cancer cells to alkylating chemotherapy agents.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:46.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma (in combination with alkylating chemotherapy)"},{"name":"Melanoma (in combination with alkylating chemotherapy)"}]},"trialDetails":[{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT01269424","phase":"PHASE1","title":"BG & TMZ Therapy of Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stanton Gerson MD","startDate":"2011-11-22","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT00669669","phase":"PHASE1, PHASE2","title":"O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-25","conditions":"Glioblastoma, Gliosarcoma","enrollment":12},{"nctId":"NCT00275002","phase":"PHASE2","title":"O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-02","conditions":"Brain and Central Nervous System Tumors","enrollment":41},{"nctId":"NCT02343666","phase":"PHASE1","title":"HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-08-15","conditions":"Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma, Stage I Adult Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT00002971","phase":"PHASE1","title":"O(6)-Benzylguanine in Treating Patients With Malignant Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"1997-06-19","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT00961220","phase":"PHASE1, PHASE2","title":"O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-01","conditions":"Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7","enrollment":17},{"nctId":"NCT00436436","phase":"PHASE2","title":"O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11-13","conditions":"Brain and Central Nervous System Tumors","enrollment":12},{"nctId":"NCT01769911","phase":"NA","title":"Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02","conditions":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma","enrollment":""},{"nctId":"NCT00020150","phase":"PHASE1","title":"Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor","enrollment":""},{"nctId":"NCT00005081","phase":"PHASE2","title":"Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma","status":"COMPLETED","sponsor":"Duke University","startDate":"2000-08","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT00612989","phase":"PHASE1","title":"Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-02","conditions":"Glioblastoma, Gliosarcoma","enrollment":42},{"nctId":"NCT00362921","phase":"PHASE2","title":"Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Duke University","startDate":"2004-04","conditions":"Recurrent Adult Brain Tumor","enrollment":52},{"nctId":"NCT00613093","phase":"PHASE2","title":"Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-10","conditions":"Glioblastoma Multiforme, Anaplastic Glioma","enrollment":67},{"nctId":"NCT00003766","phase":"PHASE1","title":"O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery","status":"COMPLETED","sponsor":"University of Chicago","startDate":"1999-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":25},{"nctId":"NCT00253487","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT00052780","phase":"PHASE1","title":"Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma","enrollment":72},{"nctId":"NCT00005066","phase":"PHASE2","title":"O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2000-06","conditions":"Sarcoma","enrollment":12},{"nctId":"NCT00006474","phase":"PHASE1","title":"Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma","status":"COMPLETED","sponsor":"Duke University","startDate":"2001-03","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT00612638","phase":"PHASE1","title":"Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-01","conditions":"Glioblastoma, Gliosarcoma","enrollment":96},{"nctId":"NCT00046878","phase":"PHASE2","title":"Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme","status":"WITHDRAWN","sponsor":"Duke University","startDate":"","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT00003348","phase":"PHASE1","title":"Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain","status":"COMPLETED","sponsor":"Duke University","startDate":"1998-05","conditions":"Brain and Central Nervous System Tumors","enrollment":56},{"nctId":"NCT00005961","phase":"PHASE2","title":"O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Melanoma (Skin)","enrollment":40},{"nctId":"NCT00003765","phase":"PHASE1","title":"O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-05","conditions":"Brain and Central Nervous System Tumors","enrollment":36},{"nctId":"NCT00017147","phase":"PHASE3","title":"S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-09","conditions":"Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System","enrollment":183},{"nctId":"NCT00086970","phase":"PHASE1","title":"Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-06","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":32},{"nctId":"NCT00003613","phase":"PHASE1","title":"O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-04","conditions":"Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT00389090","phase":"PHASE2","title":"A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma","status":"TERMINATED","sponsor":"Keryx / AOI Pharmaceuticals, Inc.","startDate":"2006-10","conditions":"Glioma, Astrocytoma, Oligodendroglioma","enrollment":32},{"nctId":"NCT00002604","phase":"PHASE1","title":"O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1996-01","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":28},{"nctId":"NCT00004072","phase":"PHASE2","title":"O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1999-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":17},{"nctId":"NCT00003567","phase":"PHASE1","title":"Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"1999-05","conditions":"Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":8},{"nctId":"NCT00005981","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-06","conditions":"Colorectal Cancer","enrollment":13},{"nctId":"NCT00045721","phase":"PHASE1","title":"Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma","status":"TERMINATED","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2003-03","conditions":"Brain and Central Nervous System Tumors","enrollment":3},{"nctId":"NCT00004892","phase":"PHASE1","title":"O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-04","conditions":"Brain and Central Nervous System Tumors","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"HEADACHE"},{"count":10,"reaction":"MENTAL STATUS CHANGES"},{"count":10,"reaction":"PYREXIA"},{"count":10,"reaction":"STAPHYLOCOCCAL INFECTION"},{"count":9,"reaction":"PULMONARY EMBOLISM"},{"count":6,"reaction":"CONVULSION"},{"count":6,"reaction":"DEEP VEIN THROMBOSIS"},{"count":6,"reaction":"POST PROCEDURAL COMPLICATION"},{"count":6,"reaction":"SOMNOLENCE"},{"count":5,"reaction":"EXTRADURAL HAEMATOMA"}],"_approvalHistory":[],"publicationCount":333,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["6-O-Benzylguanine","O(6)-Benzylguanine","06-BG","BG","O6-BG"],"phase":"phase_3","status":"active","brandName":"O6-benzylguanine","genericName":"O6-benzylguanine","companyName":"Case Comprehensive Cancer Center","companyId":"case-comprehensive-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"O6-benzylguanine is an alkyltransferase inhibitor that depletes the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), sensitizing cancer cells to alkylating chemotherapy agents. Used for Glioblastoma (in combination with alkylating chemotherapy), Melanoma (in combination with alkylating chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}